An affordable HIV-1 drug resistance monitoring method for resource limited settings

Journal of Visualized Experiments

Volumn , Issue 85, 2014, Pages

  Manasa, Justen ^a   Danaviah, Siva ^a   Pillay, Sureshnee ^a   Padayachee, Prevashinee ^a   Mthiyane, Hloniphile ^a   Mkhize, Charity ^a   Lessells, Richard John ^a   Seebregts, Christopher ^b   Rinke de Wit, Tobias F ^c   Viljoen, Johannes ^a   Katzenstein, David ^d   De Oliveira, Tulio ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b Cape Town and Durban   (South Africa)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Affordable; Antiretroviral therapy; Biomedical Technology; Drug resistance; Genetics; Genotyping; HIV Infections; HIV 1; Issue 85; Medicine; Nucleic Acids; Viremia

Indexed keywords

EID: 84898031275     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/51242     Document Type: Article

References (37)

1. Shao, Y. & Williamson, C. The HIV-1 epidemic: low-to middle-income countries. Cold Spring Harbor Persp. Med. 2, a007187, doi:10.1101/cshperspect.a007187 (2012).
2. Mutevedzi, P. C. et al. Scale-up of a decentralized HIV treatment programme in rural KwaZulu-Natal, South Africa: does rapid expansion affect patient outcomes? Bull. World Health Organ. 88, 593-600, doi:10.2471/BLT.09.069419 (2010).
3. Houlihan, C. F. et al. Cohort profile: Hlabisa HIV treatment and care programme. Int. J. Epidemiol. 40, 318-326, doi:10.1093/ije/dyp402 (2011).
4. Tanser, F., Barnighausen, T., Grapsa, E., Zaidi, J. & Newell, M. L. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 339, 966-971, doi:10.1126/science.1228160 (2013).
5. Bor, J., Herbst, A. J., Newell, M. L. & Barnighausen, T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science. 339, 961-965, doi:10.1126/science.1230413 (2013).
6. Montaner, J. S. et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 368, 531-536, doi:10.1016/S0140-6736(06)69162-9 (2006).
7. Granich, R. M., Gilks, C. F., Dye, C., De Cock, K. M. & Williams, B. G. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 373, 48-57, doi:S0140-6736(08)61697-9 [pii] 10.1016/S0140-6736(08)61697-9 (2009).
8. Johnson, L. F. et al. Life expectancies of South african adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med. 10, e1001418, doi:10.1371/journal.pmed.1001418 (2013).
9. Blower, S., Ma, L., Farmer, P. & Koenig, S. Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance. Curr. Drug Targets Infect. Dis. 3, 345-353 (2003).
10. Geretti, A. M. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr. Opin. Infect. Dis. 20, 22-32, doi:10.1097/QCO.0b013e328013caff (2007).
11. Larder, B. A., Darby, G. & Richman, D. D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 243, 1731-1734 (1989).
12. Erice, A. et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N. Engl. J. Med. 328, 1163-1165 (1993).
13. Williams, I. et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 13 Suppl 2, 1-85, doi:10.1111/j.1468-1293.2012.01029.x (2012).
14. DHHS. US Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (2012).
15. Vandamme, A. M. et al. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev. 13, 77-108 (2011).
16. DHHS. US Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. (2012).
17. Department of Health. Clinical guidelines for the management of HIV & AIDS in adults and adolescents. Department of Health (2010).
18. Conradie, F. et al. The 2012 southern African ARV drug resistance testing guidelines. S. Afr. J. HIV Med. 13, 162-167 (2012).
19. Manasa, J. et al. Primary Drug Resistance in South Africa: Data from 10 Years of Surveys. AIDS Res. Hum. Retroviruses. 28, 558-565, doi:10.1089/AID.2011.0284 (2012).
20. Tshabalala, M. et al. Surveillance of transmitted antiretroviral drug resistance among HIV-1 infected women attending antenatal clinics in Chitungwiza, Zimbabwe. PLoS ONE. 6, e21241, doi:10.1371/journal.pone.0021241 PONE-D-11-02053 [pii] (2011).
21. Bartolo, I. et al. Antiretroviral drug resistance surveillance among treatment-naive human immunodeficiency virus type 1-infected individuals in Angola: evidence for low level of transmitted drug resistance. Antimicrob. Agents Chemother. 53, 3156-3158, doi:AAC.00110-09 [pii] 10.1128/AAC.00110-09 (2009).
22. Bartolo, I. et al. HIV-1 genetic diversity and transmitted drug resistance in health care settings in Maputo, Mozambique. J. Acquir. Immune Defic. Syndr.51, 323-331 (2009).
23. Hamers, R. L. et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect. Dis. 11, 750-759, doi:S1473-3099(11)70149-9 [pii] 0.1016/S1473-3099(11)70149-9 (2011).
24. Hamers, R. L. et al. HIV-1 Drug Resistance Mutations Are Present in Six Percent of Persons Initiating Antiretroviral Therapy in Lusaka, Zambia. J. Acquir. Immune Defic. Syndr. doi:10.1097/QAI.0b013e3181e544e0 (2010).
25. Nwobegahay, J., Selabe, G., Ndjeka, N. O., Manhaeve, C. & Bessong, P. O. Low prevalence of transmitted genetic drug resistance in a cohort of HIV infected naive patients entering antiretroviral treatment programs at two sites in northern South Africa. J. Med. Virol. 84, 1839-1843, doi:10.1002/jmv.23348 (2012).
26. Iweriebor, B. C. et al. Molecular epidemiology of HIV in two highly endemic areas of northeastern South Africa. Arch. Virol. 157, 455-465, doi:10.1007/s00705-011-1180-z (2012).
27. Parboosing, R., Naidoo, A., Gordon, M., Taylor, M. & Vella, V. Resistance to antiretroviral drugs in newly diagnosed, young treatment-naive HIV-positive pregnant women in the province of KwaZulu-Natal, South Africa. J. Med. Virol. 83, 1508-1513, doi:10.1002/jmv.22143 (2011).
28. Nwobegahay, J. M. et al. Prevalence of antiretroviral drug resistance mutations and HIV-I subtypes among newly-diagnosed drug-naive persons visiting a voluntary testing and counselling centre in northeastern South Africa. J. Health Popul. Nutr. 29, 303-309 (2011).
29. Nwobegahay, J. et al. Prevalence of drug-resistant mutations in newly diagnosed drug-naive HIV-1-infected individuals in a treatment site in the waterberg district, limpopo province. S. Afr. Med. J. 101, 335-337 (2011). Department of Health, R. o. S. A. (ed Department of Health) (2013).
30. Rosen, S., Long, L., Sanne, I., Stevens, W. S. & Fox, M. P. The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. J. Int. AIDS Soc. 14, 24, doi:10.1186/1758-2652-14-24 (2011).
31. Dalai, S. C. et al. Evolution and molecular epidemiology of subtype C HIV-1 in Zimbabwe. AIDS. 23, 2523-2532, doi:10.1097/QAD.0b013e3283320ef3 (2009).
32. Chen, J. H. et al. In-house human immunodeficiency virus-1 genotype resistance testing to determine highly active antiretroviral therapy resistance mutations in Hong Kong. Hong Kong Med. J. 18, 20-24 (2012).
33. Lee, C. K. et al. An in-house HIV genotyping assay for the detection of drug resistance mutations in Southeast Asian patients infected with HIV-1. J. Med. Virol. 84, 394-401, doi:10.1002/jmv.23202 (2012).
34. Aitken, S. C. et al. A Pragmatic Approach to HIV-1 Drug Resistance Determination in Resource-Limited Settings by Use of a Novel Genotyping Assay Targeting the Reverse Transcriptase-Encoding Region Only. J. Clin. Microbiol. 51, 1757-1761, doi:10.1128/JCM.00118-13 (2013).
35. Zhou, Z. et al. Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings. PLoS One. 6, e28184, doi:10.1371/journal.pone.0028184 (2011).
36. Life_Technologies. Life Technologies and SATuRN Collaborate to Increase Access to HIV Testing in Africa, https://ir.lifetechnologies.com/releasedetail.cfm?releaseid=694585 (2012).
37. Lihana, R. W., Ssemwanga, D., Abimiku, A. & Ndembi, N. Update on HIV-1 diversity in Africa: a decade in review. AIDS Rev. 14, 83-100 (2012).